PMID-27295427 – LEADER Liraglutide Cardiovascular Outcomes Trial
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22.
Quick Reference
| Property | Value |
|---|---|
| PMID | 27295427 |
| DOI | 10.1056/NEJMoa1603827 |
| Year | 2016 |
| Journal | The New England Journal of Medicine |
| Study Type | Randomized Controlled Trial (Multicenter, Double-Blind, Placebo-Controlled) |
| Evidence Level | I |
| Sample | n=9,340 patients with T2D and high cardiovascular risk |
| Peptide(s) Studied | Liraglutide |
Key Findings
- Primary composite endpoint (CV death, nonfatal MI, nonfatal stroke): Liraglutide significantly reduced MACE vs placebo — HR 0.87 (95% CI, 0.78-0.97; p=0.01 for superiority)
- Cardiovascular death: Significantly reduced — HR 0.78 (95% CI, 0.66-0.93; p=0.007)
- All-cause mortality: Significantly reduced — HR 0.85 (95% CI, 0.74-0.97; p=0.02)
- Nonfatal MI: HR 0.88 (95% CI, 0.75-1.03; not significant)
- Nonfatal stroke: HR 0.89 (95% CI, 0.72-1.11; not significant)
- Nephropathy events: Significantly reduced — HR 0.78 (95% CI, 0.67-0.92; p=0.003)
- HbA1c reduction: Mean difference of -0.40% at 36 months favoring liraglutide
- Retinopathy events: No significant difference
- Pancreatitis: No significant difference between groups (acute pancreatitis: 18 vs 23 events)
Study Design
Double-blind, placebo-controlled, multinational RCT conducted across 410 sites in 32 countries. Patients with T2D and established CVD or CV risk factors (age >=50 with CVD, or >=60 with CV risk factors) were randomized 1:1 to liraglutide (up to 1.8 mg/day) or placebo, added to standard of care. Median follow-up was 3.8 years. Primary outcome was time to first occurrence of the 3-point MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke).
Limitations
- Enriched population with high CV risk — results may not generalize to lower-risk T2D patients
- Open-label glucose management after randomization could introduce treatment bias
- Greater use of additional glucose-lowering agents in placebo group (fewer in liraglutide group achieved glycemic targets without added therapy)
- HbA1c difference between groups could confound interpretation of whether CV benefit is glucose-independent
- Conducted before SGLT2 inhibitors became standard of care
Clinical Relevance
LEADER was the first large-scale CVOT to demonstrate cardiovascular superiority for a GLP-1 receptor agonist. The trial led the FDA to approve a CV risk reduction indication for Victoza in 2017 — the first diabetes drug approved specifically for CV benefit since the CVOT requirement was instituted in 2008. The trial established liraglutide as a preferred agent for T2D patients with established atherosclerotic cardiovascular disease, influencing ADA/EASD treatment guidelines. The mortality reduction (15% relative risk reduction in all-cause death) was particularly notable and rare among diabetes medications.
Related
#research #RCT #liraglutide #evidence-level-I #metabolic #cardiovascular